Provectus Pharmaceuticals Inc. / Twitter / TheStreet / FROVECTUS BIOPHARMACEUTICALS INC. / Pfizer / S&P / Provectus Biopharmaceuticals Inc. / Class / /
Country
Netherlands / United States / /
Currency
cent / USD / /
Event
FDA Phase / Person Communication and Meetings / Judicial Event / M&A / Name Change / Legal Issues / /
IndustryTerm
Internet message board / investigational drug product / drug product / designated such subsidiaries / manufacturing practice / pharmaceutical / media reports / treatment of several life threatening cancers / chemical supply / dermatology biopharmaceutical / treatment of melanoma / melanoma therapy / pharmaceuticals / treatment for metastatic melanoma / interstate telephone communications / non-core technologies / modem pharmaceutical standards / pharmaceutical preparations / treatment of his or her disease / chemical / over-the-counter products / medical and pharmaceutical communities / /
MedicalCondition
inflammatory dennatoses / metastatic melanoma liver cancer / skin cancer / melanoma / breast cancer / tumor / cancer / disease / speculative mania / investigational metastatic melanoma / melanoma tumors / liver cancer / diseases / several life threatening cancers / inflammation / eye disease / metastatic melanoma / /
Organization
Food and Drug Administration / FDA Oncology Division / FDA's Division of Oncology Products / Class / Congress / UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION / Securities and Exchange Commission / Moffitt Cancer Center / /
Person
CARY FARRAH / H. CRAIG DEES / TIMOTHY C. SCOTT / Craig Dees / JAMES H. HARRISON / JR. / Adam Feuerstein / PETER R. CULPEPPER / Rose Bengal / Bill Gordon / Peter Culpepper / /
Position
Chief Financial Officer / Editor / Chief Executive Officer / spokesperson / Company spokesman / Chief Operating Officer / CEO / President and a director / CFO / Chairman of the Board / /
Product
PV-10 / PV10 / PV / such a promising skin-cancer drug / PV-1 / company / Allovectin-7 / /
Cary Farrah, et al. v. Provectus Biopharmaceuticals, Inc., et al. 14-CV[removed]Complaint for Violation of the Federal Securities Laws